Lipid Abnormalities in Chronic Uremic Patients

REFERENCES

• Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169–183.
   PubMed Web of Science ®Google Scholar
• Attman P-O, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991; 39: S16–S23.
   Web of Science ®Google Scholar
• Attman P-O, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. The relation to renal function and dialysis. Nephron 1991; 57: 401–410.
   PubMed Web of Science ®Google Scholar
• Avram MM, Fein PA, Anignani A, Mittman N, Mushnick RA, Lustig AR, Lapuz MG, Goldwasser P. Cholesterol and lipid disturbances in renal disease: The natural history of uremic dyslipidemia and the impact of hemodialysis or CAPD. Am J Med 1989; 87 (5 N): 55N–61N.
   PubMedGoogle Scholar
• Bagdade JD, Casaretto A, Albers J. Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 1976; 87: 37–48.
   Web of Science ®Google Scholar
• Bagdade JD, Albers JJ. Plasma high-density lipoprotein concentrations in chronic hemodialysis and renal transplant patients. N Engl J Med 1977; 296: 1436–1439.
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Albers JJ, Haas LB, Goldberg AP, Agadoa L, Sherrard DJ. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977; 26: 903–910.
   PubMed Web of Science ®Google Scholar
• Cantaluppi A, Scalamogna A, Guerra L, Graziani G, Ponticelli C. Plasma lipid and lipoprotein levels in patients treated with CAPD. Perit Dial Bull 1982; 2: 99.
   Google Scholar
• Castillo M, Burgos C, Rodriguez Vico F, Zafra MF, Garcia-Peregrin E. Effects of clofibrate on the main regulatory enzymes of cholesterogenesis. Life Sci 1990; 46: 397–403.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Steiner G, Fenton SSA, Ampil M. Dialysis hyperlipemia: Response to dietary manipulations. Clin Nephrol 1980; 13: 177–182.
   PubMed Web of Science ®Google Scholar
• Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981; 19: 625–637.
   PubMed Web of Science ®Google Scholar
• Chan MK, Persaud JW, Varghese Z, Moorhead JF. Pathogenic roles of post-heparin lipase in lipid abnormalities in hemodialysis patients. Kidney Int 1984; 25: 812–818.
   PubMed Web of Science ®Google Scholar
• Chan MK. Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: The role of postheparin lipases in the metabolism of HDL density lipoprotein subfractions. Metabolism 1989; 38: 939–945.
   PubMed Web of Science ®Google Scholar
• Cosentini R, Blasi F, Trinchera M, Sommariva D, Fasoli A. Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate. Atherosclerosis 1989; 79: 253–255.
   PubMed Web of Science ®Google Scholar
• Culter RE. Lipid disorders in renal disease. Part 1. Prevalence, pathogenesis and diagnosis. Dial Transplant 1988; 17: 533–539.
   Google Scholar
• Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991; 31: S29–S34.
   Google Scholar
• Dieplinger H, Schoenfeld PY, Fielding CJ. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest 1986; 77: 1071–1083.
   PubMed Web of Science ®Google Scholar
• Di Giulio S, Boulu R, Drueke T, Nicolai A, Zingraff J, Crosnier J. Clofibrate treatment of hyperlipidemia in chronic renal failure. Clin Nephrol 1977; 8: 504–509.
   PubMed Web of Science ®Google Scholar
• Elisaf M, Dardamanis M, Pappas M, Sferopoulos G, Siamopoulos KC. Treatment of nephrotic hyperlipidemia with lovastatin. Clin Nephrol 1991; 36: 50–52.
   PubMed Web of Science ®Google Scholar
• Evans JE, Forland SC, Culter RE. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol 1987; 27: 994–1000.
   PubMed Web of Science ®Google Scholar
• Fridewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem 1972; 18: 499–502.
   PubMed Web of Science ®Google Scholar
• Gaw A, Shepherd J. Fibric acid derivatives. Curr Opin Lipidol 1991; 2: 39–49.
   Google Scholar
• Gokal R, Mann JI, Oliver D, Ledingham JGG, Carter RD. Treatment of hyperlipidemia in patients on chronic hemodialysis. Br Med J 1978; i: 82–83.
   Google Scholar
• Goldberg AP, Applebaum-Bowden DM, Gierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkila EA. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 1979; 301: 1073–1076.
   PubMed Web of Science ®Google Scholar
• Goldberg AP, Hagberg JM, Delmez JA, Carney RM, McKeuitt PM, Eshani AA, Harter HR. Exercise training corrects abnormal lipid and carbohydrate metabolism in hemodialysis patients. Trans Am Soc Artif Internal Organs 1979; 25: 431–437.
   PubMedGoogle Scholar
• Goldberg AP, Sherrard DJ, Haas LB, Brunzell JD. Control of clobibrate toxicity in uremic hypertriglyceridemia. Clin Phamacol Ter 1976; 21: 317–325.
   Web of Science ®Google Scholar
• Golper TA. Therapy for uremic hyperlipidemia. Nephron 1984; 38: 217–225.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Management of hyperlipidemia of kidney disease. Kidney Int 1990; 37: 847–853.
   PubMed Web of Science ®Google Scholar
• Grützmacher P, Scheuermann EH, Siede W, Lang PD, Abshagen U, Radtke HW, Baldamus CA, Schoeppe W. Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. Klin Wochenschr 1986; 64: 910–916.
   PubMedGoogle Scholar
• Grützmacher P, März W, Peschke B, Gross W, Schoeppe W. Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988; 50: 103–111.
   PubMed Web of Science ®Google Scholar
• Hamazaki T, Nakazawa R, Tateno S, Shishido H, Isoda K, Hattori Y, Yoshida T, Fujita T, Yano S, Kumagai A. Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients. Kidney Int 1984; 24: 81–84.
   Google Scholar
• Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dysli-pidemia. Safety of treatment. Changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–1245.
   PubMed Web of Science ®Google Scholar
• Ibels LS, Stewart JH, Mahony JF, Sheill AGR. Death from occlusive arterial disease in renal allograft recipients. Br Med J 1974; 3: 552–554.
   PubMedGoogle Scholar
• Keane WF, Mulcahy WS, Kasiske BL, Kim V, O'Donnell MP. Hyperlipidemia and progressive renal disease. Kidney Int 1991; 39: S41–S48.
   Web of Science ®Google Scholar
• Kijima Y, Sasaoka T, Kanayama M, Kubota S. Untowar effects of clofibrate in hemodialyzed patients. N Engl J Med 1977; 196: 515.
   Google Scholar
• Lindner A, Gharra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701.
   PubMed Web of Science ®Google Scholar
• Mendez A, Peter GO, Goldberg RB, Hsia SL. Lipid and lipoprotein levels in undialyzed patients with chronic renal failure. Am J Med Sci 1987; 283: 164–170.
   Google Scholar
• Moorhead JF. Lipids and progressive kidney disease. Kidney Int 1991; 39: S35–S40.
   Web of Science ®Google Scholar
• Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 1982; 307: 329–333.
   PubMed Web of Science ®Google Scholar
• Papadopoulos NM, Borer WZ, Elin RJ, Diamond LH. An abnormal lipoprotein in the serum of uremic patients maintained on chronic hemodialysis. Ann Intern Med 1980; 92: 634–635.
   PubMed Web of Science ®Google Scholar
• Parra FU, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33: 721.
   PubMed Web of Science ®Google Scholar
• Parsy D, Dracon M, Cachera C, Parra H-J, Vanhoutte G, Tacquet A, Fruchart J-C. Lipoprotein abnormalities in chronic hemodialysis patients. Nephrol Dial Transplant 1988; 3: 51–56.
   PubMedGoogle Scholar
• Pasternack A, Vanttinen T, Solakivi T, Kuusi T, Korte T. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987; 27: 163–168.
   PubMed Web of Science ®Google Scholar
• Pierides AM, Alvarez-Ude F, Kerr DNS. Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet 1975; 2: 1279–1282.
   PubMed Web of Science ®Google Scholar
• Rammos JM, Gokal R, Siamopoulos K, Ward MK, Wilkinson R, Kerr DNS. Continuous ambulatory pertioneal dialysis: three years experience. Q J Med 1983; 52: 165–186.
   PubMedGoogle Scholar
• Rapoport J, Aviram M, Chaimovitz C, Brook JG. Defective high-density lipoprotein composition in patients on chronic hemodialysis. N Engl J Med 1978; 299: 1326–1329.
   PubMed Web of Science ®Google Scholar
• Saku K, Sasaki J, Naito S, Avakawa K. Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron 1989; 51: 220–224.
   PubMed Web of Science ®Google Scholar
• Sanfelippo ML, Swenson RS, Reaven GM. Response of plasma triglycerides to dietary change in patients on hemodialysis. Kidney Int 1978; 14: 180–186.
   PubMed Web of Science ®Google Scholar
• Simons LA. Interrelations of lipid and lipoproteins with coronary artery disease in 19 countries. Am J Cardiol 1986; 57: G5–G10.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373–389.
   PubMed Web of Science ®Google Scholar
• Stewart JM, Packard CJ, Lorimer AR, Boag DE, Shepherd S. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis 1982; 44: 355–365.
   PubMed Web of Science ®Google Scholar
• Vessby B, Lithell H. Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridemic patients. Atherosclerosis 1990; 82: 137–143.
   PubMed Web of Science ®Google Scholar
• Wanner C, Hörl NH. Carnitine abnormalities in patients with renal insufficiency. Pathophysiologic and therapeutic aspects. Nephron 1988; 50: 89–102.
   PubMed Web of Science ®Google Scholar
• Wanner C, Wieland H, Nauck M, Schaeffer G, Schollmeyer P, Hörl WH. Effective hypolipidaemic therapy with beclobrate in haemodialysis patients. Interference with L-carnitine. Nephrol Dial Transplant 1990; 5: 588–593.
   PubMed Web of Science ®Google Scholar
• Wanner C, Hörl WH, Luley CH, Wieland H. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney 1991; 39: 754–760.
   Google Scholar